See more : OKYO Pharma Limited (EMMLF) Income Statement Analysis – Financial Results
Complete financial analysis of Amylyx Pharmaceuticals, Inc. (AMLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amylyx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Prismo Metals Inc. (PRIZ.CN) Income Statement Analysis – Financial Results
- Club De Futbol Intercity Sad (CITY.MC) Income Statement Analysis – Financial Results
- Shenzhen Kedali Industry Co., Ltd. (002850.SZ) Income Statement Analysis – Financial Results
- Billing System Corporation (3623.T) Income Statement Analysis – Financial Results
- Damara Gold Corp. (DMR.V) Income Statement Analysis – Financial Results
Amylyx Pharmaceuticals, Inc. (AMLX)
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 380.79M | 22.23M | 285.00K | 650.00K | 1.43M |
Cost of Revenue | 25.44M | 2.99M | 52.00K | 24.59M | 11.90M |
Gross Profit | 355.35M | 19.24M | 233.00K | -23.94M | -10.47M |
Gross Profit Ratio | 93.32% | 86.54% | 81.75% | -3,683.69% | -734.43% |
Research & Development | 128.19M | 93.45M | 44.04M | 24.59M | 11.90M |
General & Administrative | 178.86M | 127.13M | 38.93M | 15.06M | 3.08M |
Selling & Marketing | 9.50M | 4.40M | 0.00 | 0.00 | 0.00 |
SG&A | 188.36M | 127.13M | 38.93M | 15.06M | 3.08M |
Other Expenses | 0.00 | 3.74M | -285.00K | -650.00K | -1.43M |
Operating Expenses | 316.54M | 220.58M | 82.69M | 39.01M | 13.55M |
Cost & Expenses | 341.98M | 223.57M | 82.69M | 39.01M | 13.55M |
Interest Income | 16.16M | 4.29M | 36.00K | 14.00K | 176.00K |
Interest Expense | 0.00 | 4.29M | 0.00 | 2.29M | 1.28M |
Depreciation & Amortization | 1.09M | 487.00K | 52.00K | 1.00K | 13.55M |
EBITDA | 39.89M | -200.85M | -82.64M | -39.00M | 1.11M |
EBITDA Ratio | 10.48% | -905.72% | -29,013.33% | -5,957.08% | -938.22% |
Operating Income | 38.80M | -201.34M | -82.69M | -39.01M | -13.55M |
Operating Income Ratio | 10.19% | -905.72% | -29,013.33% | -6,000.77% | -950.49% |
Total Other Income/Expenses | 15.50M | 3.74M | -5.24M | -3.28M | -162.00K |
Income Before Tax | 54.30M | -197.60M | -87.93M | -42.28M | -13.72M |
Income Before Tax Ratio | 14.26% | -888.89% | -30,852.98% | -6,504.62% | -961.85% |
Income Tax Expense | 5.03M | 774.00K | -52.00K | 2.56M | 1.10M |
Net Income | 49.27M | -198.38M | -87.88M | -44.84M | -14.82M |
Net Income Ratio | 12.94% | -892.38% | -30,834.74% | -6,898.00% | -1,038.99% |
EPS | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
EPS Diluted | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
Weighted Avg Shares Out | 67.23M | 66.51M | 57.86M | 56.47M | 56.47M |
Weighted Avg Shares Out (Dil) | 69.99M | 66.51M | 57.86M | 56.47M | 56.47M |
Levi & Korsinsky Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX
Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLX
Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) should contact Levi & Korsinsky about pending Class Action - AMLX
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – AMLX
Levi & Korsinsky Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX
Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) Seeking Recovery for Investors - Contact Levi & Korsinsky
Source: https://incomestatements.info
Category: Stock Reports